A Prospective, Real-World Study EvalUating the EffectiveNess and Safety of RISankizumab in PatiEnts With Ulcerative Colitis (SUNRISE-UC)
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Risankizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms SUNRISE-UC
- 13 Jan 2025 New trial record